(3RB) Reckitt Benckiser - Ratings and Ratios
Health, Hygiene, Nutrition, Personal Care, Supplements, Disinfectant
Description: 3RB Reckitt Benckiser
Reckitt Benckiser Group plc is a multinational consumer goods company that produces a diverse range of health, hygiene, and nutrition products. The companys product portfolio includes well-known brands such as Dettol, Durex, Nurofen, and Lysol, among others, catering to various consumer needs. With a presence in multiple markets globally, Reckitt Benckiser has established itself as a significant player in the personal care products industry.
To evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, profit margins, and return on equity (RoE). With a RoE of 27.04%, Reckitt Benckiser demonstrates a strong ability to generate profits from shareholder equity. Additionally, the companys diverse product portfolio and global presence likely contribute to its resilience against market fluctuations. Other relevant KPIs could include the companys dividend yield, debt-to-equity ratio, and operating cash flow margin.
Reckitt Benckisers product categories span germ protection, intimate wellness, and nutrition, among others, indicating a strategy focused on meeting fundamental consumer needs. The companys brand portfolio is diversified across various categories, potentially reducing dependence on any single brand or market. By analyzing the companys brand performance, market share, and competitive positioning, we can gain insights into its growth prospects and ability to maintain its market presence.
From a valuation perspective, the companys price-to-earnings (P/E) ratio of 24.41 and forward P/E of 14.75 suggest that the market expects earnings growth in the future. To further assess the companys valuation, we could examine metrics such as the price-to-book ratio, enterprise value-to-EBITDA, and compare these to industry averages. This analysis would help determine whether Reckitt Benckisers stock is fairly valued, overvalued, or undervalued relative to its peers and the broader market.
3RB Stock Overview
| Market Cap in USD | 50,188m |
| Sub-Industry | Personal Care Products |
| IPO / Inception |
3RB Stock Ratings
| Growth Rating | 12.7% |
| Fundamental | 77.0% |
| Dividend Rating | 52.0% |
| Return 12m vs S&P 500 | 9.40% |
| Analyst Rating | - |
3RB Dividends
| Dividend Yield 12m | 4.57% |
| Yield on Cost 5y | 3.81% |
| Annual Growth 5y | 2.37% |
| Payout Consistency | 98.1% |
| Payout Ratio | 110.1% |
3RB Growth Ratios
| Growth Correlation 3m | 61.1% |
| Growth Correlation 12m | 71.9% |
| Growth Correlation 5y | -57.5% |
| CAGR 5y | -2.44% |
| CAGR/Max DD 5y | -0.07 |
| Sharpe Ratio 12m | 0.18 |
| Alpha | 21.19 |
| Beta | 0.148 |
| Volatility | 20.88% |
| Current Volume | 2.6k |
| Average Volume 20d | 4.3k |
| Stop Loss | 61.9 (-3%) |
| Signal | 0.04 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.12b TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -0.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -18.68% (prev -13.65%; Δ -5.03pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 3.17b > Net Income 2.12b (YES >=105%, WARN >=100%) |
| Net Debt (7.78b) to EBITDA (7.30b) ratio: 1.07 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (701.7m) change vs 12m ago -2.33% (target <= -2.0% for YES) |
| Gross Margin 60.56% (prev 58.94%; Δ 1.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.32% (prev 81.98%; Δ -13.66pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.39 (EBITDA TTM 7.30b / Interest Expense TTM 393.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.38
| (A) -0.13 = (Total Current Assets 4.60b - Total Current Liabilities 7.94b) / Total Assets 25.30b |
| (B) 0.87 = Retained Earnings (Balance) 21.99b / Total Assets 25.30b |
| warn (B) unusual magnitude: 0.87 — check mapping/units |
| (C) 0.16 = EBIT TTM 4.08b / Avg Total Assets 26.22b |
| (D) 0.35 = Book Value of Equity 6.45b / Total Liabilities 18.58b |
| Total Rating: 3.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.99
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.22% = 3.11 |
| 3. FCF Margin 15.53% = 3.88 |
| 4. Debt/Equity 1.26 = 1.76 |
| 5. Debt/Ebitda 1.16 = 1.54 |
| 6. ROIC - WACC 11.30% = 12.50 |
| 7. RoE 27.04% = 2.25 |
| 8. Rev. Trend 18.48% = 0.92 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -39.22% = -0.98 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of 3RB shares?
Over the past week, the price has changed by -1.66%, over one month by -1.12%, over three months by +10.66% and over the past year by +27.96%.
Is Reckitt Benckiser a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of 3RB is around 57.67 EUR . This means that 3RB is currently overvalued and has a potential downside of -9.66%.
Is 3RB a buy, sell or hold?
What are the forecasts/targets for the 3RB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 62.8 | -1.6% |
3RB Fundamental Data Overview
Market Cap GBP = 37.15b (43.09b EUR * 0.8621 EUR.GBP)
CCE Cash And Equivalents = 880.0m GBP (Cash And Short Term Investments, last quarter)
P/E Trailing = 29.8216
P/E Forward = 16.2075
P/S = 3.0814
P/B = 5.8911
P/EG = 4.4679
Beta = 0.066
Revenue TTM = 17.91b GBP
EBIT TTM = 4.08b GBP
EBITDA TTM = 7.30b GBP
Long Term Debt = 7.01b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.42b GBP (from shortTermDebt, last quarter)
Debt = 8.44b GBP (Calculated: Short Term 1.42b + Long Term 7.01b)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 44.70b GBP (37.15b + Debt 8.44b - CCE 880.0m)
Interest Coverage Ratio = 10.39 (Ebit TTM 4.08b / Interest Expense TTM 393.0m)
FCF Yield = 6.22% (FCF TTM 2.78b / Enterprise Value 44.70b)
FCF Margin = 15.53% (FCF TTM 2.78b / Revenue TTM 17.91b)
Net Margin = 11.81% (Net Income TTM 2.12b / Revenue TTM 17.91b)
Gross Margin = 60.56% ((Revenue TTM 17.91b - Cost of Revenue TTM 7.06b) / Revenue TTM)
Tobins Q-Ratio = 6.94 (Enterprise Value 44.70b / Book Value Of Equity 6.45b)
Interest Expense / Debt = 4.66% (Interest Expense 393.0m / Debt 8.44b)
Taxrate = 31.94% (from yearly Income Tax Expense: 672.0m / 2.10b)
NOPAT = 2.78b (EBIT 4.08b * (1 - 31.94%))
Current Ratio = 0.58 (Total Current Assets 4.60b / Total Current Liabilities 7.94b)
Debt / Equity = 1.26 (Debt 8.44b / last Quarter total Stockholder Equity 6.70b)
Debt / EBITDA = 1.16 (Net Debt 7.78b / EBITDA 7.30b)
Debt / FCF = 3.03 (Debt 8.44b / FCF TTM 2.78b)
Total Stockholder Equity = 7.82b (last 4 quarters mean)
RoA = 8.36% (Net Income 2.12b, Total Assets 25.30b )
RoE = 27.04% (Net Income TTM 2.12b / Total Stockholder Equity 7.82b)
RoCE = 27.52% (Ebit 4.08b / (Equity 7.82b + L.T.Debt 7.01b))
RoIC = 17.23% (NOPAT 2.78b / Invested Capital 16.12b)
WACC = 5.93% (E(37.15b)/V(45.58b) * Re(6.56%)) + (D(8.44b)/V(45.58b) * Rd(4.66%) * (1-Tc(0.32)))
Shares Correlation 5-Years: -20.0 | Cagr: -0.47%
Discount Rate = 6.56% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈2.95b ; Y1≈1.94b ; Y5≈887.2m
Fair Price DCF = 25.71 (DCF Value 17.44b / Shares Outstanding 678.3m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 18.48 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -30.94
EPS Correlation: -39.22 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -4.22